当前位置:产品中心 > 细胞系 > TAA > DLL > H_DLL3 HEK-293 Cell Line
H_DLL3 HEK-293 Cell Line
基本信息

产品编号:GM-C12896

产品名称:H_DLL3 HEK-293 Cell Line

目录价:询价

细胞培养、冻存、复苏试剂准备

生长培养基:DMEM+10% FBS+1% P.S+0.75 μg/mL Puromycin

冻存培养基:90% FBS+10% DMSO


简介

基于HEK293细胞,使用慢病毒技术构建的稳定表达H_DLL3的单克隆细胞系。


H_DLL3氨基酸序列


MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYL


数据展示
文献引用

Lin S, Zhang Y, Yao J, Yang J, Qiu Y, Zhu Z, Hua H. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. 2024 Aug 14;22(1):766. PMID: 39143619; PMCID: PMC11323672.

当前位置:产品中心 > 细胞系 > TAA > DLL > H_DLL3 HEK-293 Cell Line

H_DLL3 HEK-293 Cell Line
基本信息

产品编号:GM-C12896

产品名称:H_DLL3 HEK-293 Cell Line

目录价:询价

细胞培养、冻存、复苏试剂准备

生长培养基:DMEM+10% FBS+1% P.S+0.75 μg/mL Puromycin

冻存培养基:90% FBS+10% DMSO


简介

基于HEK293细胞,使用慢病毒技术构建的稳定表达H_DLL3的单克隆细胞系。


H_DLL3氨基酸序列


MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYL


数据展示
文献引用

Lin S, Zhang Y, Yao J, Yang J, Qiu Y, Zhu Z, Hua H. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. 2024 Aug 14;22(1):766. PMID: 39143619; PMCID: PMC11323672.

Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交